Post
Oncternal doses first patient in trial of B cell lymphoma therapy
Oncternal Therapeutics has dosed the first patient in its Phase I/II trial of ONCT-808, a ROR1 targeting autologous CAR T …
LianBio reports positive topline data from gastric cancer therapy trial
LianBio has reported positive topline results from a Phase IIa trial of infigratinib for the treatment of locally advanced or …
QurAlis receives authorisation to initiate ALS therapy trial in EU
QurAlis has received clinical trial authorisation (CTA) in the European Union (EU) to initiate a first-in-human, Phase I ANQUR clinical …
BPGbio doses first patients in Phase II GBM therapy trial
BPGbio has dosed the first patients in a Phase II clinical trial of BPM 31510 to treat Glioblastoma Multiforme (GBM), …
ASCO 2023: blockbuster Enhertu demonstrates efficacy across multiple tumour types
At the American Society of Clinical Oncology (ASCO) Annual Meeting, 2-6 June 2023, interim results were presented for the Phase …
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
FDA open for feedback on GCP draft guidance
The US Food and Drug Administration (FDA) released a draft guidance with updated recommendations for good clinical practices (GCPs). The draft …
IDE clinical trial for artificial cervical disc completes enrollment
Synergy Spine Solutions has enrolled the last patient in its investigational device exemption (IDE) clinical trial. The 1-Level Synergy Disc …
ASCO 2023: Precigen reports positive early data for CAR-T therapy
New early data suggests Precigen Therapeutics’s CAR-T therapy PRGN-3005 could decrease tumour burden in advanced ovarian cancer. In Phase I data …
Synlogic begins Phase III trial of SYNB1934 for phenylketonuria
US-based biotechnology firm Synlogic has begun a Phase III trial of SYNB1934 for the treatment of phenylketonuria (PKU), a rare …
FogPharma doses first patient in colorectal cancer drug trial
US-based biopharmaceutical company FogPharma has dosed the first patient in its first-in-human Phase I/II clinical trial of FOG-001, a TCF-blocking …
Imbria completes patient enrolment in trial of nHCM therapy
US-based pharmaceutical company Imbria Pharmaceuticals has finished enrolling patients in its IMPROVE-HCM Phase II clinical trial of ninerafaxstat for non-obstructive …
ANeuroTech receives FDA approval for Phase IIIb MDD drug trial
The US Food and Drug Administration (FDA) has given clearance to ANeuroTech’s investigational new drug (IND) application, allowing the company …
EyePoint completes patient enrolment in study of NPDR therapy
US-based pharmaceutical company EyePoint Pharmaceuticals has finished enrolling patients in its Phase II PAVIA clinical trial of EYP-1901 for moderate …
Bellerophon’s study of fILD therapy fails to meet primary endpoint
US-based biotechnology firm Bellerophon Therapeutics has reported that its Phase III REBUILD clinical trial of INOpulse for the treatment of …
ASCO 2023: AstraZeneca’s PD-1/TIGIT shows promise in checkpoint-exposed NSCLC
Lung cancer is the second most common cancer globally, with non-small cell lung cancer (NSCLC) being the most common lung …